lobbying_activities: 2815655

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2815655	2e005744-91c0-4421-842e-a8b2851d337e	Q2	CHAMBER HILL STRATEGIES	400645947	BIOMARIN PHARMACEUTICAL INC.	2022	second_quarter	MMM	Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, access to treatment through telehealth, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021, and in H.R.3684 - Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. H.R. 7489, Medicaid VBPs for Patients Act or the MVP Act.	Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE	30000		0	0	2022-07-08T12:37:01-04:00